Campath (Intravenous)

Campath (Intravenous) Uses, Dosage, Side Effects, Food Interaction and all others data.

Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.

Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.

Table Of contents

• Campath (Intravenous)
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Campath (Intravenous)
Availability	Prescription only
Generic	Alemtuzumab
Alemtuzumab Other Names	Alemtuzumab
Related Drugs	Gilenya, Tysabri, Venclexta, Vumerity, rituximab, Rituxan, cyclophosphamide, Copaxone, Imbruvica, Tecfidera
Type
Formula	C6468H10066N1732O2005S40
Weight	145453.8 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	USA
Last Updated:	September 19, 2023 at 7:00 am

Uses

Campath (Intravenous) is a monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.

Campath (Intravenous) (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.

Campath (Intravenous) is also used to associated treatment for these conditions: Autoimmune Hemolytic Anemia, B-Cell Chronic Lymphocytic Leukemia, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), T-Cell Prolymphocytic Leukemia, Conditioning regimens for allogeneic stem cell transplantation therapy

How Campath (Intravenous) works

Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

Food Interaction

No interactions found.

Campath (Intravenous) Drug Interaction

Major: teriflunomide, teriflunomideModerate: aspirin, aspirin, dimethyl fumarate, dimethyl fumarateUnknown: acetaminophen, acetaminophen, charcoal, charcoal, alprazolam, alprazolam, dalfampridine, dalfampridine, pseudoephedrine / triprolidine, pseudoephedrine / triprolidine, interferon beta-1a, interferon beta-1a, sodium iodide, sodium iodide

Campath (Intravenous) Disease Interaction

Major: cytopeniasModerate: cardiac/pulmonary disease, infections

Volume of Distribution

• 0.18 L/kg

Half Life

~288 hrs

Innovators Monograph

You find simplified version here Campath (Intravenous)